Proteomics bags US patent for endometriosis test
Brought to you by BULLS AND BEARS
Murray Region
Proteomics International Laboratories has been awarded a vital US patent for its innovative PromarkerEndo blood test, a move that gives it a commercial edge in the world’s largest healthcare market and validates a key part of its global strategy.
The United States Patent and Trademark Office (USPTO) has granted a new patent for the company’s new diagnostic test for endometriosis. This painful condition affects one in nine women and currently takes an average of seven years to be diagnosed, often requiring invasive surgery.
The PromarkerEndo test for endometriosis, which now holds a US patent, could significantly shorten the path to diagnosis for a condition with a well-known history of frustrating delays. Proteomics pegs the potential US market at 360,000 tests per year.
The patent, titled ‘Endometriosis Biomarkers’, covers methods for diagnosing the condition using specific protein biomarkers in blood samples.
‘This significantly strengthens our position on future partnerships, licensing discussions and regulatory reimbursement progress.’
David Morris, managing director and chief executive officer of Proteomics International Laboratories
Specifically, it provides intellectual property protection in the US until March 2041 and strengthens the company’s hand in future partnerships and licensing negotiations. The patent also appears likely to ease the all-important path to regulatory reimbursement, where the government and health insurers set a standard payment rate for the test.
David Morris, managing director and chief executive officer of Proteomics International Laboratories, said:: “The granting of this patent by the USPTO is a great achievement and an important validation of PromarkerEndo’s innovation and commercial potential.”
The latest milestone is more than just a single win; It’s another plan in a much broader strategic pivot for the Perth-based company.
Proteomics, under new chief executive and chief executive David Morris, has clawed its way through the long research phase and is now moving towards what every listed biotech eventually needs: commercial traction.
In a new strategy presentation, the company outlined a disciplined three-year plan to transform its proteomics science platform into a scalable diagnostics business. For smaller life sciences players, the transition from lab to sales ledger may be the toughest hurdle, but Proteomics appears to be aware of the challenge.
The company chose a capital-light route, leaning on distribution partners rather than building expensive in-house sales teams. Management says this model will enable earlier market adoption, reduce enterprise risk and deliver better capital efficiency.
While the new patent sheds light on PromarkerEndo, it is just one of four tests in the company’s portfolio. Leading the charge is PromarkerD, a blood test that predicts diabetes-related chronic kidney disease up to four years before symptoms appear. Proteomics estimates there is a targetable market of 390,000 tests annually in the US alone.
Another offering, PromarkerEso, is designed to help rule out throat cancer in chronic reflux patients by replacing potentially invasive endoscopies with a simple blood test.
Rounding out the stable is OxiDx, an oxidative stress testing platform that could find a home in specialist medicine and even elite athletics and equine markets.
The company says it has laid out its road map in careful stages. Proteomics plans to appoint an Australian distributor and launch locally controlled market releases for PromarkerEndo in the first half of fiscal 2027. In the second half, it is aimed to establish the US distribution network and initiate refund applications in both countries.
This payback angle could be the real reward. In Australia, a listing in the Medicare Assistance Program is expected to significantly expand access for patients. In the US, success often comes from the payer; It’s a slower but potentially more profitable route once momentum is built.
With a revamped board, a new CEO with commercialization experience, four products launched, and a key US patent now secured, Proteomics appears to be entering a phase where the market may begin to ask not just what the science can do, but what its future revenue pipeline might look like.
Is your ASX-listed company doing something interesting? Contact: mattbirney@bullsnbears.com.au
